☆ 4.8 Article

A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia

JOURNAL OF CLINICAL INVESTIGATION (2021)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

R. Libster et al.

Summary: A randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV-2 in older adult patients within 72 hours after the onset of mild Covid-19 symptoms found that early administration of high-titer convalescent plasma reduced the progression of Covid-19 in mildly ill infected older adults.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

M. J. Joyner et al.

Summary: This study found that higher anti-SARS-CoV-2 IgG antibody levels in convalescent plasma were associated with a lower risk of death among patients hospitalized with Covid-19 who were not receiving mechanical ventilation. The association between antibody levels and mortality risk was moderated by mechanical ventilation status, with no significant effect seen in patients who had already received ventilation.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

V. A. Simonovich et al.

Summary: There were no significant differences observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo in the treatment of severe Covid-19 pneumonia. The study results indicate that both groups had similar clinical outcomes and mortality rates after 30 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Microbiology

SARS-CoV-2 Genomic Variation in Space and Time in Hospitalized Patients in Philadelphia

John Everett et al.

Summary: The first wave of COVID-19 in Philadelphia showed similarities with lineages from New York, suggesting primary transmission from that location, but also indicated local spread. Some patients had heterogeneous viral populations within them, with variations in genome sequences between time points and body sites. There was no clear link between different lineages and disease outcomes, underscoring the importance of individual-specific vulnerability.

MBIO (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection

Elizabeth M. Anderson et al.

Summary: Our research indicates that most individuals had antibodies against other seasonal human coronaviruses before the COVID-19 pandemic. Around 20% of these individuals also had antibodies that cross-reacted with SARS-CoV-2, but these antibodies did not offer protection against SARS-CoV-2 infections or hospitalizations.

CELL (2021)

Add to Collection

Review Medicine, General & Internal

The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis

Stephen A. Klassen et al.

Summary: Studies show that COVID-19 convalescent plasma can lower mortality rates in patients, especially when administered early and with higher antibody titers.

MAYO CLINIC PROCEEDINGS (2021)

Add to Collection

Review Microbiology

The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19

Arturo Casadevall et al.

Summary: Antibody therapies like convalescent plasma and monoclonal antibodies have emerged as potential treatments for COVID-19, following the principles of specificity, temporality, and quantity in administering specific antibodies early in the disease course. Historical lessons suggest that antibody therapy is most effective when used early in respiratory diseases.

MBIO (2021)

Add to Collection

Article Medicine, General & Internal

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Peter W. Horby et al.

Summary: Convalescent plasma therapy did not improve survival or other clinical outcomes in hospitalized COVID-19 patients.

LANCET (2021)

Add to Collection

Article Medicine, Research & Experimental

Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): updates study protocol for an international, multicentre, randomized, open-label trial

Philippe Begin et al.

Summary: CONCOR-1 is a randomized controlled trial investigating the efficacy and safety of COVID-19 convalescent plasma in patients with SARS-CoV-2 infection, with the primary outcome being intubation or death at day 30. The trial will also provide information on the role and thresholds of SARS-CoV-2 antibody titres and neutralization assays for donor qualification.

TRIALS (2021)

Add to Collection

Article Multidisciplinary Sciences

Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19

Neima Briggs et al.

Summary: The study found that early administration of CCP can improve outcomes in patients with moderate-to-severe COVID-19, while improvement was not observed with late administration of CCP. Timing of administration should be considered in future trials.

PLOS ONE (2021)

Add to Collection

Article Mathematical & Computational Biology

Prospective individual patient data meta-analysis: Evaluating convalescent plasma for COVID-19

Keith S. Goldfeld et al.

Summary: This paper proposes an innovative approach for pooling patient-level data from multiple ongoing randomized clinical trials (RCTs) that have not been configured as a network of sites, aiming to find answers in weeks or months, rather than years. Although focusing on RCTs for convalescent plasma (CP) for COVID-19, the proposed framework is generally applicable to pooling data from RCTs for other therapies and disease settings.

STATISTICS IN MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors

Katie L. Kunze et al.

Summary: Successful COVID-19 therapeutics and vaccines have utilized the immune response to the virus, but locally-evolving variants may impact treatment effectiveness. Near-sourced convalescent plasma has higher efficacy in causing death within 30 days of transfusion.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Biology

Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality

Arturo Casadevall et al.

Summary: The usage of COVID-19 convalescent plasma (CCP) therapy in the USA was high in Fall 2020 but steadily declined in Spring 2021. A strong inverse correlation between CCP usage and mortality per admission was found, with a possible association between the decline in CCP usage and excess deaths during the pandemic.

ELIFE (2021)

Add to Collection

Article Medicine, Research & Experimental

A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia

Cristina Avendano-Sola et al.

Summary: The study conducted in Spain involving 27 hospitals showed that convalescent plasma (CP) can significantly reduce the risk of progression to invasive mechanical ventilation or ECMO treatment, or death within 28 days for COVID-19 patients. However, the difference was not significant at 14 days and there was no significant improvement in overall survival.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Medicine, Research & Experimental

A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19

Max R. O'Donnell et al.

Summary: This study found that the use of convalescent plasma was not associated with significant improvement in the clinical status at day 28 for severe COVID-19 patients, but it was related to significantly improved survival rates.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Medicine, General & Internal

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Chenguang Shen et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Multidisciplinary Sciences

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Kai Duan et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Add to Collection

Article Immunology

Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019

Qing-Lei Zeng et al.

JOURNAL OF INFECTIOUS DISEASES (2020)

Add to Collection

Article Medicine, Research & Experimental

Endpoints for randomized controlled clinical trials for COVID-19 treatments

Lori E. Dodd et al.

CLINICAL TRIALS (2020)

Add to Collection

Article Oncology

High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR

Souad Assaad et al.

EUROPEAN JOURNAL OF CANCER (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Pooling Data From Individual Clinical Trials in the COVID-19 Era

Eva Petkova et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 A Randomized Clinical Trial

Ling Li et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Immunology

SARS-CoV-2 seroprevalence among parturient women in Philadelphia

Dustin D. Flannery et al.

SCIENCE IMMUNOLOGY (2020)

Add to Collection

Article Medicine, Research & Experimental

Early safety indicators of COVID-19 convalescent plasma in 5000 patients

Michael J. Joyner et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Review Infectious Diseases

A potentially effective treatment for COVID-19: A systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease

Mengyao Sun et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)

Add to Collection

Article Medicine, General & Internal

Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis

Stephanie L. Harrison et al.

PLOS MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19

Ning Rosenthal et al.

JAMA NETWORK OPEN (2020)

Add to Collection

Article Mathematical & Computational Biology

A rank test for bivariate time-to-event outcomes when one event is a surrogate

Pamela A. Shaw et al.

STATISTICS IN MEDICINE (2016)

Add to Collection

Article Immunology

Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)

Scott R. Evans et al.

CLINICAL INFECTIOUS DISEASES (2015)

Add to Collection

Article Cardiac & Cardiovascular Systems

The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities

Stuart J. Pocock et al.

EUROPEAN HEART JOURNAL (2012)

Add to Collection

Article Infectious Diseases

Use of convalescent plasma therapy in SARS patients in Hong Kong

Y Cheng et al.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2005)

Add to Collection

Article Infectious Diseases

Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients

YOY Soo et al.

CLINICAL MICROBIOLOGY AND INFECTION (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.